Journal
THERAPEUTIC ADVANCES IN HEMATOLOGY
Volume 12, Issue -, Pages -Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/20406207211038193
Keywords
acquired haemophilia A; bypassing agents; emicizumab
Categories
Ask authors/readers for more resources
Acquired haemophilia A is a rare and severe hemorrhagic autoimmune disease caused by autoantibodies against factor VIII. Treatment involves hemostatic control and immunosuppressive therapy, which can be challenging given the elderly population with comorbidities. Emicizumab, a bispecific antibody, has shown promise in managing AHA patients with comorbidities.
Acquired haemophilia A (AHA) is a rare and severe haemorrhagic autoimmune disease caused by autoantibodies directed against factor VIII (FVIII). Treatment is based on two principles, including haemostatic control to compensate FVIII inhibition and eradication of inhibiting antibodies using immunosuppressive therapy. Rapid recognition and proper management are essential to avoid excess morbidity and mortality. Effective and safe treatments can be challenging, given that AHA patients are often elderly, with multiple comorbidities. Emicizumab, a bispecific antibody that mimics the action of FVIII, has proven effective in managing patients with congenital haemophilia, with or without inhibitors. Likewise, its mode of action suggests theoretical efficacy in AHA patients. We herein describe two AHA cases with comorbidities that were treated effectively using emicizumab combined with immunosuppressive therapy. We have also reviewed the current literature regarding the promising use of emicizumab in this indication.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available